Claims
- 1. An adenovirus vector comprising an adenovirus gene under transcriptional control of a probasin transcriptional regulatory element (PB-TRE).
- 2. The adenovirus vector of claim 1, wherein the adenovirus gene is essential for viral replication.
- 3. The adenovirus vector of claim 2. wherein the adenovirus gene is an early gene.
- 4. The adenovirus of claim 2, wherein the adenovirus gene is a late gene.
- 5. The adenovirus vector of claim 3, wherein the adenovirus early gene is E1A.
- 6. The adenovirus vector of claim 3, wherein the adenovirus early gene is E1B.
- 7. The adenovirus vector of claim 1, wherein the adenovirus gene is the adenovirus death protein gene (ADP).
- 8. The adenovirus vector of claim 1, wherein the PB-TRE comprises an enhancer from a probasin gene.
- 9. The adenovirus vector of claim 1, wherein the PB-TRE comprises a promoter from a probasin gene.
- 10. The adenovirus vector of claim 1, wherein the PB-TRE comprises a promoter from a probasin gene and an enhancer from a probasin gene.
- 11. The adenovirus vector of claim 1, wherein the PB-TRE comprises at least one androgen response element (ARE).
- 12. The adenovirus vector of claim 1, wherein the PB-TRE comprises androgen response elements 1 and 2 (ARE-1 and ARE-2) of a probasin gene.
- 13. The adenovirus vector of claim 1, wherein the PB-TRE comprises nucleotides about 141 to about 454 of SEQ ID NO:1.
- 14. The adenovirus vector of claim 1, wherein the PB-TRE comprises nucleotides about 191 to about 204 or about 286 to about 310 of SEQ ID NO:1.
- 15. The adenovirus vector of claim 1, wherein the PB-TRE comprises nucleotides about 191 to about 204 and about 286 to about 310 of SEQ ID NO:1.
- 16. The adenovirus vector of claim 1, wherein the PB-TRE comprises the sequence of SEQ ID NO:1.
- 17. A composition comprising an adenovirus of claim 1.
- 18. A composition of claim 17, further comprising a pharmaceutically acceptable excipient.
- 19. The adenovirus of claim 1, further comprising at least one additional adenovirus gene under transcriptional control of at least one additional prostate-specific transcriptional regulatory element.
- 20. The adenovirus of claim 19, wherein the at least one additional prostate-specific transcriptional regulatory element comprises a PB-TRE.
- 21. The adenovirus of claim 19, wherein the at least one additional prostate-specific transcriptional regulatory element comprises a prostate-specific antigen (PSA) transcriptional regulatory element.
- 22. A composition comprising an adenovirus of claim 19.
- 23. The composition of claim 22. further comprising a pharmaceutically acceptable excipient.
- 24. An adenovirus vector of claim 1, further comprising a heterologous gene under transcriptional control of a probasin transcriptional regulatory element (PB-TRE).
- 25. The vector of claim 24, wherein the heterologous gene is a reporter gene.
- 26. The vector of claim 24, wherein the heterologous gene is conditionally required for cell survival.
- 27. A host cell transformed with an adenovirus vector of claim 1.
- 28. A host cell transformed with an adenovirus vector of claim 19.
- 29. A method of detecting cells which allow a PB-TRE to function in a biological sample comprising the steps of:
contacting a biological sample with an adenovirus vector of claim 1, under conditions suitable for PB-TRE-mediated gene expression in cells which allow a PB-TRE to function; and determining if PB-TRE mediates gene expression in the biological sample, wherein PB-TRE-mediated gene expression is indicative of the presence of cells which allow a PB-TRE to function.
- 30. The method of claim 29, in which cells which allow a PB-TRE to function express androgen receptor.
- 31. A method of propagating an adenovirus specific for cells which allow a PB-TRE to function, said method comprising:
combining an adenovirus according to claim 1 with cells which allow a PB-TRE to function, whereby said adenovirus is propagated.
- 32. A method of propagating an adenovirus specific for mammalian cells which allow a PB-TRE to function, said method comprising:
combining an adenovirus according to claim 19 with mammalian cells which allow a PB-TRE to function, whereby said adenovirus is propagated.
- 33. A method for modifying the genotype of a target cell, said method comprising contacting a cell which allows a PB-TRE to function with an adenovirus of claim 1, wherein the adenovirus enters the cell.
- 34. A method for modifying the genotype of a target cell, said method comprising contacting a cell which allows a PB-TRE to function with an adenovirus of claim 19, wherein the adenovirus enters the cell.
- 35. A method for conferring selective cytotoxicity on a target cell, said method comprising contacting a cell which allows a PB-TRE to function with an adenovirus vector of claim 1, wherein the adenovirus vector enters the cell.
- 36. A method for conferring selective toxicity on a target cell, said method comprising contacting a cell which allows a PB-TRE to function with an adenovirus vector of claim 19, wherein the adenovirus vector enters the cell.
- 37. A method of suppressing tumor cell growth, said method comprising contacting a tumor cell with an adenoviral vector of claim 1 such that the adenoviral vector enters the tumor cell and exhibits selective cytotoxicity for the tumor cell.
- 38. A method of suppressing tumor cell growth, said method comprising contacting a tumor cell with an adenoviral vector of claim 19 such that the adenoviral vector enters the tumor cell and exhibits selective cytotoxicity for the tumor cell.
- 39. A method of treating prostate cancer in an individual, comprising the step of administering to the individual an effective amount of an adenovirus vector of claim 2.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Patent Application Serial No. 60/039,762, filed on Mar. 3, 1997.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60039762 |
Mar 1997 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09614495 |
Jul 2000 |
US |
Child |
10222479 |
Aug 2002 |
US |
Parent |
09033333 |
Mar 1998 |
US |
Child |
09614495 |
Jul 2000 |
US |